compounded semaglutide diarrhea and Why Does Semaglutide Cause Diarrhea? FDA Warns on Certain Forms

China is expected to grow at a CAGR of 7.1%, reflecting the rising burden of diabetes in the country, along with growing access to modern therapies like GLP-1 Receptor Agonists for better diabetes management

That is a massive reduction

Claims for GLP-1s Increased Four-Fold Between 2019 and 2024 In accordance with an increase in both the number of Medicare Part D enrollees using GLP-1s and spending on these products, the number of claims for GLP-1s increased four-fold between 2019 and 2024, from 4.8 million to 21.8 million, with claims doubling between 2022 and 2024 alone

2015 Dec 10;10(12):e0144231

What the Data Shows The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, randomized 2,539 adults with obesity to tirzepatide at 5, 10, or 15 mg weekly or placebo for 72 weeks (3)

In the GLP-1 era, that is more important than ever